Compare VRA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | LCTX |
|---|---|---|
| Founded | 1982 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.9M | 301.7M |
| IPO Year | 2010 | 1996 |
| Metric | VRA | LCTX |
|---|---|---|
| Price | $3.95 | $1.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 468.0K | ★ 2.1M |
| Earning Date | 06-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $416,097,000.00 | $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $1.39 | $0.93 |
| 52 Week High | $4.39 | $2.09 |
| Indicator | VRA | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 51.70 |
| Support Level | $2.17 | N/A |
| Resistance Level | $4.37 | $1.32 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 65.25 | 55.65 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.